Cipla Ltd’s
stock is currently experiencing a positive trend, with analysts maintaining a
“Buy” consensus and projecting moderate growth for the near term.
Analyst
Ratings & Price Targets :-
- Consensus Rating: The average analyst rating for Cipla Ltd is “Buy,” with 24 “Buy,” 8 “Hold,” and 5 “Sell” recommendations. Investing.com
- 12-Month Price Target: Analysts have set an average 12-month price target of ₹1,640.92, indicating an approximate 10.87% upside from the current price of ₹1,480.00.
Financial Performance Highlights :-
- Recent Earnings: In the third quarter of FY25, Cipla reported a 93% year-on-year increase in consolidated net profit, reaching ₹983 crore, while revenue rose by 1.4% to ₹13,286 crore.
- EBITDA Growth: Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) for Q3FY25 stood at ₹1,809 crore, reflecting a 3.4% increase on a quarter-on-quarter basis and a 57.8% rise year-on-year.
Market Considerations
Despite the
positive outlook, analysts caution that broader market volatility, influenced
by geopolitical tensions and economic uncertainties, could impact stock
performance. However, Cipla is considered a relatively safer investment within
the pharmaceutical sector.
In summary,
Cipla Ltd’s stock is on an upward trajectory, supported by strong financial
performance and positive analyst ratings. Investors with a medium to long-term
horizon may consider accumulating the stock, keeping in mind the potential for
continued growth and the broader market environment.
Investment in securities market are subject to market risks. Read and agree Disclaimer and related all the documents carefully before investing, mentioned on www.nikhilbhatt.in
